Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EKZ-102
- Development stage
- Preclinical
- Lead developer
- Eikonizo Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
EKZ-102 is an oral, small molecule, histone deacetylase 6 (HDAC6) inhibitor being developed by Eikonizo Therapeutics. It is characterized by high potency, selectivity, and CNS penetrance, designed to protect neuronal function while minimizing potential off-target side effects. EKZ-102 has a dual mechanism approach targeting both intracellular transport and proteostasis defects, which are key drivers of neurodegenerative disease biology. It is primarily being developed for the treatment of Amyotrophic Lateral Sclerosis (ALS) and other neurodegenerative diseases, with potential to be a first-in-class, disease-modifying therapy.
02
Targets
HDAC6 (Histone deacetylase 6)
Beyond the preview
Go deeper on EKZ-102.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EKZ-102.